MX336476B - Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. - Google Patents
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.Info
- Publication number
- MX336476B MX336476B MX2012001745A MX2012001745A MX336476B MX 336476 B MX336476 B MX 336476B MX 2012001745 A MX2012001745 A MX 2012001745A MX 2012001745 A MX2012001745 A MX 2012001745A MX 336476 B MX336476 B MX 336476B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- breast cancer
- patient
- previously treated
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
- G06Q30/0251—Targeted advertisements
- G06Q30/0269—Targeted advertisements based on user profile or attribute
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Business, Economics & Management (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Strategic Management (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Development Economics (AREA)
- Accounting & Taxation (AREA)
- Finance (AREA)
- Immunology (AREA)
- Marketing (AREA)
- Economics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Entrepreneurship & Innovation (AREA)
- Biomedical Technology (AREA)
- Game Theory and Decision Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
La presente invención se refiere a un anticuerpo anti-VEGF en la manufactura de un medicamento para tratar a un paciente diagnosticado con cáncer de mama triple negativo metastásico previamente tratado, en donde el paciente debió haber recibido una quimioterapia para la enfermedad metastásica en un tratamiento de primera línea, en donde el paciente es sometido a un régimen de tratamiento que combina una quimioterapia como una terapia de segunda línea para tratar el cáncer de mama metastásico previamente tratado con la administración de una cantidad efectiva de un anticuerpo anti-VEGF, que comprende una región variable de cadena pesada que tiene la siguiente secuencia de aminoácidos (SEQ ID NO. 1), y una región variable de cadena ligera que comprende la siguiente secuencia de aminoácidos: (SEQ ID NO. 2), en donde la quimioterapia del régimen de tratamiento en la terapia de segunda línea comprende la administración de al menos un agente quimioterapéutico, seleccionado del grupo que consiste en terapia con taxano, capecitabina, gemcitabina y vinorelbina, y en donde el régimen de tratamiento extiende efecgtivamente la supervivencia libre de progreso del paciente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23428109P | 2009-08-15 | 2009-08-15 | |
| US26634309P | 2009-12-03 | 2009-12-03 | |
| PCT/US2010/045147 WO2011022264A1 (en) | 2009-08-15 | 2010-08-11 | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012001745A MX2012001745A (es) | 2012-03-21 |
| MX336476B true MX336476B (es) | 2016-01-20 |
Family
ID=42830354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001745A MX336476B (es) | 2009-08-15 | 2010-08-11 | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20110047103A1 (es) |
| EP (2) | EP2464381A1 (es) |
| JP (2) | JP6088246B2 (es) |
| KR (1) | KR20120107069A (es) |
| CN (1) | CN102573909A (es) |
| AR (1) | AR077848A1 (es) |
| AU (2) | AU2010284446A1 (es) |
| BR (1) | BR112012003346A2 (es) |
| CA (1) | CA2771086A1 (es) |
| CL (1) | CL2012000387A1 (es) |
| CO (1) | CO6612209A2 (es) |
| CR (1) | CR20120076A (es) |
| IL (1) | IL218007A0 (es) |
| MA (1) | MA33579B1 (es) |
| MX (1) | MX336476B (es) |
| NZ (1) | NZ598131A (es) |
| PH (1) | PH12012500296A1 (es) |
| RU (1) | RU2576027C2 (es) |
| SG (2) | SG178419A1 (es) |
| TW (2) | TWI451875B (es) |
| WO (1) | WO2011022264A1 (es) |
| ZA (1) | ZA201200998B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| JOP20170053B1 (ar) * | 2016-03-02 | 2021-08-17 | Eisai Randd Man Co Ltd | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها |
| CN111050784B (zh) * | 2017-08-11 | 2024-03-19 | 伊利诺伊大学理事会 | 截短的豚鼠l-天冬酰胺酶变体及其使用方法 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| KR100870353B1 (ko) * | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| CN101665536B (zh) | 1997-04-07 | 2013-07-03 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| RU2270029C2 (ru) * | 1999-06-25 | 2006-02-20 | Джинентех, Инк. | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR20160014775A (ko) | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
-
2010
- 2010-08-11 BR BR112012003346A patent/BR112012003346A2/pt active Search and Examination
- 2010-08-11 NZ NZ598131A patent/NZ598131A/en not_active IP Right Cessation
- 2010-08-11 EP EP10747115A patent/EP2464381A1/en not_active Withdrawn
- 2010-08-11 TW TW099126812A patent/TWI451875B/zh not_active IP Right Cessation
- 2010-08-11 WO PCT/US2010/045147 patent/WO2011022264A1/en not_active Ceased
- 2010-08-11 US US12/854,711 patent/US20110047103A1/en not_active Abandoned
- 2010-08-11 CN CN2010800464523A patent/CN102573909A/zh active Pending
- 2010-08-11 RU RU2012109932/15A patent/RU2576027C2/ru active
- 2010-08-11 MX MX2012001745A patent/MX336476B/es unknown
- 2010-08-11 PH PH1/2012/500296A patent/PH12012500296A1/en unknown
- 2010-08-11 KR KR1020127006656A patent/KR20120107069A/ko not_active Abandoned
- 2010-08-11 EP EP16171215.3A patent/EP3090758A1/en not_active Withdrawn
- 2010-08-11 JP JP2012524835A patent/JP6088246B2/ja active Active
- 2010-08-11 CA CA2771086A patent/CA2771086A1/en not_active Abandoned
- 2010-08-11 SG SG2012010377A patent/SG178419A1/en unknown
- 2010-08-11 AR ARP100102939 patent/AR077848A1/es unknown
- 2010-08-11 SG SG2013073556A patent/SG194395A1/en unknown
- 2010-08-11 TW TW102139989A patent/TW201431558A/zh unknown
- 2010-08-11 AU AU2010284446A patent/AU2010284446A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218007A patent/IL218007A0/en unknown
- 2012-02-10 ZA ZA2012/00998A patent/ZA201200998B/en unknown
- 2012-02-14 CL CL2012000387A patent/CL2012000387A1/es unknown
- 2012-02-14 CR CR20120076A patent/CR20120076A/es unknown
- 2012-02-20 CO CO12029506A patent/CO6612209A2/es unknown
- 2012-03-12 MA MA34681A patent/MA33579B1/fr unknown
-
2014
- 2014-11-17 US US14/543,588 patent/US20150071924A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015240828A patent/JP2016117718A/ja active Pending
-
2016
- 2016-05-09 AU AU2016202976A patent/AU2016202976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201431558A (zh) | 2014-08-16 |
| CL2012000387A1 (es) | 2012-10-05 |
| SG178419A1 (en) | 2012-04-27 |
| CO6612209A2 (es) | 2013-02-01 |
| IL218007A0 (en) | 2012-04-30 |
| SG194395A1 (en) | 2013-11-29 |
| JP2016117718A (ja) | 2016-06-30 |
| WO2011022264A1 (en) | 2011-02-24 |
| TWI451875B (zh) | 2014-09-11 |
| KR20120107069A (ko) | 2012-09-28 |
| AU2016202976A1 (en) | 2016-05-26 |
| JP2013501801A (ja) | 2013-01-17 |
| RU2012109932A (ru) | 2013-09-20 |
| BR112012003346A2 (pt) | 2016-11-16 |
| NZ598131A (en) | 2014-08-29 |
| MA33579B1 (fr) | 2012-09-01 |
| US20110047103A1 (en) | 2011-02-24 |
| CN102573909A (zh) | 2012-07-11 |
| JP6088246B2 (ja) | 2017-03-01 |
| ZA201200998B (en) | 2013-05-29 |
| RU2576027C2 (ru) | 2016-02-27 |
| US20150071924A1 (en) | 2015-03-12 |
| AU2010284446A1 (en) | 2012-03-08 |
| TW201109032A (en) | 2011-03-16 |
| EP2464381A1 (en) | 2012-06-20 |
| MX2012001745A (es) | 2012-03-21 |
| CA2771086A1 (en) | 2011-02-24 |
| EP3090758A1 (en) | 2016-11-09 |
| AR077848A1 (es) | 2011-09-28 |
| CR20120076A (es) | 2012-05-29 |
| PH12012500296A1 (en) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336476B (es) | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. | |
| FI4241849T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| UY31800A (es) | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb | |
| EP4272757A3 (en) | Modified nk-92 cells for treating cancer | |
| NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| RU2014119150A (ru) | Модулирование некоторых тирозинкиназ | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
| FI2694072T4 (fi) | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa | |
| NZ708506A (en) | Methods of treating bladder cancer | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| WO2010135534A3 (en) | Compositions for the treatment of metastatic cancer and methods of use thereof | |
| AR035227A1 (es) | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus | |
| RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| MX2017010763A (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
| MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
| ES2482342A1 (es) | TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2014013380A (es) | Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana. | |
| Andreola et al. | Who should be really considered as a poor mobilizer in the plerixafor era? | |
| US20210052660A1 (en) | Neural stem cell compositions including chimeric poxviruses for cancer treatment | |
| RU2013130449A (ru) | Способ комбинированного лечения рака прямой кишки |